Patent Challenges Via IPR Still Pretty Scary, Even After Acorda's Win
This article was originally published in The Pink Sheet Daily
Executive Summary
Reform efforts gain steam, but hedge fund manager Kyle Bass' attack on Acorda's patents was denied based on specifics of prior art, not biotech's arguments about abuse of the system.
You may also be interested in...
Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up
In an unusual twist, district court ruled Acorda patents invalid after company defeated Kyle Bass' inter partes review challenge; Bass has won 10 IPR decisions, lost 9 and has one pending.
Biogen Secures First-Round Patent Win For Tecfidera; One More To Go
PTAB rejected an inter partes review challenge to a key patent protecting the oral multiple sclerosis blockbuster to 2028 in the US, but another challenge remains outstanding.
Acorda Defeats Kyle Bass, Now Awaits Ruling In Ampyra ANDA Litigation
Patent Trial and Appeal Board upheld validity of four Acorda patents; district court judge to issue decision on five patents. Victory would block generic competition until 2025.